Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 11 Show results per page	View Search Criteria \| Help With Results


1.		Vaccine Treatment for Hormone Refractory Prostate Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				19 and over				Pharmaceutical / Industry				NLG0103 398-04FB, NCT00105053


2.		Vaccine Treatment for Advanced Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				NLG0104 OBA#0404-640, NCT00300612

Last Modified: 4/20/2007


3.		Phase II Study of Active Intralymphatic Immunotherapy With Interferon Alfa-Treated Allogeneic Tumor Cells Plus Sargramostim (GM-CSF) and Cyclophosphamide in Patients With Advanced Pancreatic Adenocarcinoma (Summary Last Modified 06/2001)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Other				SVMC-ONC-222P NCI-V96-0886, NCT00002773

Last Modified: 12/20/2007


4.		Phase II Pilot Study of Cyclophosphamide and Active Intralymphatic Immunotherapy With a Vaccine Containing Interferon alfa or Interferon gamma-Treated Tumor Cells Followed By Sargramostim (GM-CSF) in Patients With Advanced Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Other				SVMC-ONC-222 NCI-V91-0075, NCT00002475

Last Modified: 7/23/2007 First Published: 1/24/2005


5.		Phase II Study of Adjuvant Vaccine Therapy Comprising Autologous Dendritic Cells Loaded With Allogeneic Non-small Cell Lung Cancer (NSCLC) Cells in Patients With Unresectable Stage IIIA or IIIB, or Resected Stage I-IIIB NSCLC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 to 80				NCI, Other				UKMC-IRB-0391-F2R UKMC-CTRF-G-01-009, NCT00103116

Last Modified: 12/27/2008


6.		Immunotherapy with BCG with or without Irradiated Allogeneic Cells for Stage I Lung Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Closed				no age specified								NCI-LUN-1

Last Modified: 12/27/2008


7.		Allogeneic Tumor Cells During Intensive Maintenance Chemotherapy After Induction with ARA-C/ADR for Acute Myelocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Closed				Under 70								RPMI-DMA-970701 NCI-D78-026-209

Last Modified: 12/28/2008


8.		Surgical Resection, Chemotherapy with CTX/ADR, Radiotherapy and Immunotherapy with BCG and Tumor Cells for Neuroblastoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Closed				under 18								SJCRH-NB-1 SJCRH-NB-74

Last Modified: 12/28/2008


9.		Chemotherapy plus BCG Immunotherapy with or without Allogeneic Tumor Cells for Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Closed				no age specified								SWE-LGMS-AML-1

Last Modified: 12/28/2008


10.		Chemotherapy with Adriamycin/Cyclophosphamide with or without BCG/Tumor Cell Vaccine Immunotherapy for Lung Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	No phase specified				Treatment				Closed				no age specified								UARIZ-IIIB

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute